Back to journals
Academic JournalOpen Access

Translational Psychiatry

32 Papers Indexed in Blossom

Data updated

Research Footprint

Translational Psychiatry has 32 tracked papers indexed in Blossom (2014–2026) from 226 authors, most often covering Psilocybin, Ketamine and LSD, across Depressive Disorders, Neuroimaging & Brain Measures and Healthy Volunteers.

Published Papers

Open Accessindividual

Comparison of acute effects of 3,4-methylenedioxymethamphetamine (MDMA) with and without a supplemental booster dose in healthy participants: a double-blind, randomized, placebo-controlled, crossover study

This double-blind, randomised, placebo-controlled crossover study (n=25) in healthy volunteers found that a 60 mg MDMA booster dose given 2 hours after 120 mg MDMA prolonged the subjective drug effects, but did not increase peak effects. Adverse effects were more common after both MDMA conditions than after placebo.

Published
Journal
Translational Psychiatry
Authors
Humbert-Droz, M., Becker, A. M., Valenta, J., Rudin, D., Luethi, D., Vukalovic, I., Eckert, A., Liechti, M. E., Mueller, L.
Open Accessindividual

Epigenome-wide association study of psilocybin-induced methylome changes in alcohol use disorder

This longitudinal randomised study (n=37) in detoxified patients with alcohol use disorder examined DNA methylation changes after psilocybin 25 mg versus placebo and found one psilocybin-linked methylation site, plus broader changes related to depression and drinking measures. The changes involved genes and pathways linked to neuroplasticity and immune function.

Published
Journal
Translational Psychiatry
Authors
Urban, M. M., Zillich, L., Rieser, N. M., Herdener, M., Spanagel, R., Vollenweider, F. X., Preller, K. H., Meinhardt, M. W.
Open Accessindividual

Dose-dependent pharmacokinetics and acute effects of intravenous bolus N,N-dimethyltryptamine: double-blind, randomized versus open-label dose-escalation administration study in healthy participants

This double-blind, randomised, placebo-controlled crossover study and separate open-label dose-escalation study (n=36) in healthy participants examined intravenous DMT and found that it produced very strong but short-lived subjective effects, peaking within 2 minutes and fading within 12 to 30 minutes. The strongest effects levelled off at 15 mg, and dose escalation appeared to improve tolerability compared with blinded dosing.

Published
Journal
Translational Psychiatry
Authors
Erne, L., Mueller, L., Straumann, I., Ademaj, B., Eckert, A., Vukalovic, I., Valenta, J., Luethi, D., Liechti, M. E., Vogt, S. B.
Open Accessindividual

Negative affective bias in depression following treatment with psilocybin or escitalopram - a secondary analysis from a randomized trial

In a double-blind randomised trial of patients with long-standing moderate-to-severe depression, two doses of psilocybin plus placebo and six weeks of escitalopram produced comparable reductions in negative affective bias on a facial emotion recognition task at the six-week endpoint. Changes in bias were not associated with concurrent symptom change, although improved recognition of positive faces predicted symptom improvement at week 10 only in the escitalopram group, suggesting partially overlapping but distinct cognitive mechanisms.

Published
Journal
Translational Psychiatry
Authors
Martens, M. A. G., Cunha, B. G., Erritzoe, D., Nutt, D., Carhart-Harris, R., Harmer, C. J.
Open Accessmeta

Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis

This cost-effectiveness analysis found that psilocybin-assisted therapy (PAT) for treatment-resistant depression (TRD) may offer economic value at $5,000 or less per treatment course, yielding an incremental cost-effectiveness ratio of $117,517 per QALY gained over 12 months, with cost-effectiveness highly sensitive to treatment price (95% probability at $3,000 vs 1% at $10,000).

Published
Journal
Translational Psychiatry
Authors
Avancena, A. L. V., Vuong, L., Kahn, J. G., Marseille, E.
Open Accessmeta

Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology

This systematic review (2024) and meta-analysis (s=44) finds that medium/high doses of LSD yield higher ratings of visionary restructuralisation than psilocybin. It also reports that psychedelics strengthen between-network functional connectivity and diminish within-network connectivity, and that LSD induces more inositol phosphate formation at the 5-HT2A receptor than DMT or psilocin, while receptor selectivity differences remain negligible.

Published
Journal
Translational Psychiatry
Authors
Shinozuka, K., Jerotic, K., Mediano, P. A. M., Zhao, A. T., Preller, K. H., Carhart-Harris, R. L., Kringelbach, M. L.

Quick Facts

Papers Indexed
32
h-Index
137
Open Access
Yes
Publisher
Nature Portfolio
Country
United Kingdom
Website
Visit